Core Insights - CENTOGENE and Critical Path Institute (C-Path) have signed a Memorandum of Understanding (MOU) to enhance drug development for lysosomal diseases (LDs) and improve patient quality of life [4][11] - The partnership aims to leverage genetic and real-world data to address challenges in developing safe and effective therapies for LDs [2][5] Company Overview - CENTOGENE is a global leader in genomic and multiomic testing services, focusing on rare and neurodegenerative diseases, with over 850,000 patients represented in its Biodatabank from more than 120 countries [10][13] - C-Path is a nonprofit organization established in 2005, recognized for its role in accelerating drug development through collaborations involving various stakeholders [8][12] Partnership Details - The MOU outlines collaborative efforts to enhance data enrichment and linkage for specific lysosomal diseases, provide genetic testing services, and offer sample analysis reporting [6][11] - The partnership will also promote joint branding efforts to highlight the unique collaboration in the field of real-world and genetic data for lysosomal diseases [6][11] Strategic Goals - The collaboration aims to combine expertise and resources to overcome significant barriers in lysosomal disease research and drug development [11] - C-Path's Critical Path for Lysosomal Diseases (CPLD) Consortium, established in 2023, focuses on accelerating drug development through public-private partnerships [5][8]
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development